SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-12-15			5-day change	1st Jan Change
10.26 ^CNY	+0.10%		-0.68%	-14.07%

Dec. 12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
Dec. 01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT

Shyndec Pharmaceutical's Chairman, President Resign

Published on 08/28/2024 at 05:36 am EDT - Modified on 08/28/2024 at 05:47 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Dec. 12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
Dec. 01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
Nov. 04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
Oct. 29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
Oct. 29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
Oct. 17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
Oct. 13	Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate	MT
Sep. 23	Shyndec Pharmaceutical's Subsidiary Gets Nod to Add Specification to Vitamin B6 Injection	MT
Sep. 18	Shyndec Pharma's Enalapril Maleate Tablets Passes Regulator's Consistency Evaluation	MT
Sep. 17	Shyndec Pharmaceutical Gets Registration Certification for Penehyclidine Hydrochloride Injection	MT
Sep. 01	Shyndec Pharma Obtains Drug Registration for Chest Pain Drug	MT
Aug. 29	Shanghai Shyndec Pharmaceutical H1 net profit down 6.5% Y/Y	RE
Aug. 08	Shyndec Pharma's Unit Gets Nod to Market Ketamine Hydrochloride	MT
Jul. 29	Shyndec Pharmaceutical's Subsidiaries Get Registration Certificates for Two Drugs	MT
Jul. 18	Shyndec Pharmaceutical's H1 Profit Slips 7%, Total Revenue Drops 18%	MT
Jul. 17	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
Jul. 17	Shanghai Shyndec Pharmaceutical prelim H1 net profit down 6.5% Y/Y	RE
Jul. 01	Shyndec Pharmaceutical Unit Gets Registration Certificate for Hypertension Drug in China	MT
Jun. 05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT
Jun. 05	Shyndec Pharma Gets Registration Certificate for Hypertension Drug	MT
May. 29	Shanghai Shyndec Pharmaceutical Gets Approval for Anti-Tumor Injection	MT
May. 14	Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	MT
Apr. 28	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
Apr. 16	Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	MT
Mar. 27	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

Mar. 26 - Q4 2025 Earnings Release (Projected)

More about the company